BOTALYS
We make the impossible sourcing of rare medicinal plants flawless
We make the impossible sourcing of rare medicinal plants flawless
BOTALYS is a biotechnology startup based in Belgium, founded in 2011. The company's slogan, "We make the impossible sourcing of rare medicinal plants flawless," encapsulates its mission.
BOTALYS specializes in sourcing rare medicinal plants and employs biomimetic farming technology to cultivate these plants under ideal conditions, resulting in high-quality botanical ingredients. Its flagship product is the Korean Red Ginseng, for which the company has developed a full-spectrum ginseng root powder comparable to a 20-year-old wild Korean ginseng specimen.
The company's last investment was a significant €639.99K Series B investment on 25 May 2023. BOTALYS operates in the biotechnology and healthcare industries, catering to meticulous brands in search of premium botanical ingredients.
With its commitment to sustainability and innovation, BOTALYS presents an intriguing prospect for potential investors seeking opportunities in the biotechnology and healthcare sectors.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | €639.99K | - | 25 May 2023 | |
| Series B | €6.65M | 5 |
|
04 Oct 2022 |
| Series B | €5.00M | 3 |
|
14 Jan 2020 |
| Series A | €140.15K | 1 |
|
24 Apr 2019 |
| Grant | €2.21M | 1 | Horizon 2020 | 26 Mar 2019 |
We care about your data, and we'd love to use cookies make your experience better.
